DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20171652

Aflibercept for diabetic macular edema: a concise review

Sujithera Haridoss, Soundaram Meenakshi Sundaram, Melvin George, Damal Kandadai Sriram

Abstract


Diabetic retinopathy and diabetic macular edema are associated with loss of vision in patients with diabetes worldwide. The treatment requires a multidisciplinary interventional approach. Among the available management options for DME, laser photocoagulation has been the standard of care. Due to its slow progression and inability to reverse the vision loss, an alternative treatment is needed. The role of vascular endothelial growth factors (VEGF) and inflammatory mediators led to the development of anti-VEGF agents, that stimulates retinal vasculogenesis and angiogenesis. Intravitreal aflibercept is an anti-angiogenic soluble decoy receptor with trap technology employed by fusion of multiple endogeneous receptor component, approved for the treatment of DME. Clinical trials of aflibercept comparing it with laser photocoagulation and other anti-VEGF have shown reliable efficacy, providing significantly positive visual and anatomical results. However, treatment regimens with monthly clinical visits and injections, challenge the patients comfort, thereby requiring the need to identify better strategies to lower injection frequencies.


Keywords


Aflibercept, Drug, Diabetic Retinopathy, Diabetic macular edema, New therapy

Full Text:

PDF

References


King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-31.

Lihteh Wu, Sauma J, Loaiza PF, Hernandez-Bogantes E, Masis M. Classification of diabetic retinopathy and diabetic macular edema. World J Diabet. 2013;4(6):290-4.

Das T, Rani A. Diabetic eye diseases in foundations of ophthalmology, New Delhi, Jaypee Publisher; 2006:54-55.

Lang GE. Diabetic macular edema. Ophthalmol. 2012;227:21-9.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factorin ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7.

Thai HT, Veyrat-Follet C, Vivier N, Dubruc C, Sanderink G, Mentre F, et al. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol. 2011;72(3):402-14.

Papadopoulos N, Martin, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogen. 2012;15:171-85.

Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmol. 2012;119(8):1658-65.

Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmol. 2011;118(9):1819-26.

Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema, 148-week results from the VISTA and VIVID Studies. Ophthalmol. 2016;123(11):2376-85.

Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmol. 2010;117(6):1078-86.

Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina. 2009;29(3):292-9.

Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, et al. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes- Protocol 3 with high dose). Eye (Lond). 2015;29(12):1538-44.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmol. 2012;119(4):789-801.

Celik N, Scheuerle A, Auffarth G. Pharmacokinetics of aflibercept and vascular endothelial growth factor-A. Invest Ophthalmol Vis Sci. 2015;56(9):5574-8.

Eylea aflibercept. Tarrytown, NY: Regeneron Pharmaceuticals, 2016. Available at http://www. ajmc.com/journals/supplement/2016/improving-outc omes-in-diabetic-macular-edema-the-impact-of-new-therapies-in-managed-care/current-approaches-to-the-management-of-diabetic-macular-edema/p-4#sthash.yRHuekn3.dpuf.

Brown DM, Schmidt-Erfurth U, Do DV. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID Studies. Ophthalmol. 2015;122(10):2044-52.

Kitchens JW, Do DV, Boyer DS, Thompson D, Gibson A, Saroj N, et al. Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials. Ophthalmol. 2016;123(7):1511-20.

Avery R, Castellarin AA, Steinle NC, Dhoot D S, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636-41.

Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye. 2016:1-11.